Effect of interleukin-15 on alloreactivity in umbilical cord blood.
Interleukin(IL)-15 is a promising immunotherapeutic agent for immune reconstitution following stem cell transplantation. To investigate whether IL-15 would aggravate graft-versus-host disease (GVHD) in the setting of unrelated umbilical cord blood (CB) transplantation, we examined the effect of IL-15 on activation marker expression, proliferation and cytokine production of CB in a one-way mixed lymphocyte culture (MLC) assay. We found that IL-15 differentially enhanced CD69 and CD25 expression on CB T cells following allo-stimulation. The maximum degree of allo-specific CB proliferation was achieved on Day 6. IL-15 down-regulated the CB alloreactive proliferative response on Days 4, 6, and 8, with preferentially enhanced autologous proliferation. Exogenous IL-15 further enhanced CB TNF-alpha and IL-10 production in both autologous and allogeneic MLC 6 days after allopriming. Thus, IL-15 was effective in enhancing activation marker expression and cytokine production during CB alloreactivity, but failed to enhance allospecific proliferation. Further studies would be needed to study the role of IL-15 on GVHD in the setting of CB transplantation.
Lin
Syh-Jae
SJ
Division of Allergy and Immunology, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Chang Gung Children's Hospital, 5 Fu-Hsing Street, Kwei-Shan, Taoyuan, Taiwan. sjlino@cgmh.org.tw
Cheng
Po-Jen
PJ
Yan
Dah-Chin
DC
Lee
Pei-Tzu
PT
Hsaio
Hsiu-Shan
HS
D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005312:Fetal Blood / Q000276:immunology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology; D019409:Interleukin-15 / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D037181:Lectins, C-Type; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016753:Interleukin-10; D019409:Interleukin-15; D037181:Lectins, C-Type; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D000099192:CD69 Antigens